BANB:SWX
BACHEM HOLDING AG
CHFÂ 81.65
arrow_upward
+1.05%(+0.85) 1D
Nov 4, 5:31:16 PM GMT+1 · CHF
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BANB...
Open
CHFÂ 81.00
High
CHFÂ 82.35
Low
CHFÂ 79.95
Mkt. cap
6.12B
Avg. vol.
85.92K
Volume
82.52K
Dividend
1.10%
Quarterly dividend
CHFÂ 0.22
Ex-dividend date
May 4, 2026
P/E ratio
41.17
52-wk high
CHFÂ 86.00
52-wk low
CHFÂ 48.52
EPS
CHFÂ 1.98
Shares outstanding
75.00M
No. of employees
3K
Open
CHFÂ 81.00
High
CHFÂ 82.35
Low
CHFÂ 79.95
Mkt. cap
6.12B
Avg. vol.
85.92K
Volume
82.52K
Dividend
1.10%
Quarterly dividend
CHFÂ 0.22
Ex-dividend date
May 4, 2026
P/E ratio
41.17
52-wk high
CHFÂ 86.00
52-wk low
CHFÂ 48.52
EPS
CHFÂ 1.98
Shares outstanding
75.00M
No. of employees
3K
News stories
From web sources and news partners
Virginia Business
·
48 minutes ago
Accendra Health could be delisted by NYSE
Forbes
·
9 minutes ago
Dow Gains 1,500 Points After Election Despite Musk, AI-Linked Stocks Finishing Down
Yahoo Finance
·
31 minutes ago
The Nasdaq-100 Is Outperforming Nvidia, Microsoft, Amazon, Meta Platforms, Alphabet, and Tesla This Year. Here's My Favorite Low-Cost ETF to Buy the Dip.
The Washington Post
·
2 hours ago
The S&P 500 climbs after Democrats sweep the midterms
Profile
Bachem Holding AG is a Swiss biotechnology company specializing in the development and manufacture of peptides and complex organic molecules for use as active pharmaceutical ingredients. The company focuses on peptide-based therapeutics, including large-scale commercial production and process development for pharmaceutical applications. It was founded in 1971 and is a subsidiary of Ingro Finanz AG.
The head office is in Bubendorf in the canton of Basel-Landschaft. Bachem operates production facilities in Vionnaz, Vista and Torrance, and St Helens, as well as a sales and distribution site in Tokyo.
Bachem is one of the largest manufacturers of peptide-based APIs globally, supplying pharmaceutical and biotechnology companies with products used in both clinical development and commercial therapies.
In recent years, the company has expanded its manufacturing capacity, including new large-scale production facilities in Switzerland and the United States.
At the end of 2025, the company employed 2,511 people, reported revenue of CHF 695.1 million, and net income of CHF 148.8 million. Wikipedia
About BACHEM HOLDING AG